Many clinical trials initiated since 2022 have explored the use of psychedelic substances derived from mushrooms in the treatment of depression. These studies aim to assess safety, efficacy, and potential benefits of using psychedelic compounds in mental health care. The trials are conducted under controlled environments, often involving carefully monitored dosages and professional supervision. The focus is on understanding how these substances interact with neural pathways associated with mood regulation and psychological well-being. Results from some of these studies have shown promising signs of symptom reduction and improved patient outcomes, although they are yet to be universally adopted or formalized into standard practice. Regulatory bodies continue to evaluate the scientific evidence, and ongoing research seeks to clarify the mechanisms and long-term implications of using psychedelic therapies for depression.

_2_

The discourse surrounding the medical use of psychedelics remains highly polarized, with proponents highlighting potential breakthroughs in treatment-resistant cases and opponents emphasizing the need for caution due to safety concerns. Despite the mixed opinions, the scientific community maintains a focus on rigorous research and data collection to ensure that any new therapies are both effective and safe. As studies progress, the potential integration of psychedelic-based treatments into conventional mental health care pipelines may evolve, depending on forthcoming evidence and regulatory decisions. In this context, the ongoing research serves as a critical step toward expanding treatment options for individuals suffering from depression, with the aim of determining whether these substances can provide sustainable and manageable alternatives to existing therapies.